AU2002210982A1 - Method of screening antiplatelet - Google Patents

Method of screening antiplatelet

Info

Publication number
AU2002210982A1
AU2002210982A1 AU2002210982A AU1098202A AU2002210982A1 AU 2002210982 A1 AU2002210982 A1 AU 2002210982A1 AU 2002210982 A AU2002210982 A AU 2002210982A AU 1098202 A AU1098202 A AU 1098202A AU 2002210982 A1 AU2002210982 A1 AU 2002210982A1
Authority
AU
Australia
Prior art keywords
screening
sub
tool
antiplatelet agent
antiplatelet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002210982A
Inventor
Masazumi Kamohara
Mitsuyuki Matsumoto
Takahide Ohishi
Tetsu Saito
Takatoshi Soga
Jun Takasaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamanouchi Pharmaceutical Co Ltd
Original Assignee
Yamanouchi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharmaceutical Co Ltd filed Critical Yamanouchi Pharmaceutical Co Ltd
Publication of AU2002210982A1 publication Critical patent/AU2002210982A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

A screening tool for an antiplatelet agent wherein the tool is a human ADP receptor P2T<SUB>AC </SUB>protein, a variation functionally equivalent thereto, or a homologous protein thereof, and a screening tool for an antiplatelet agent wherein the tool is a transformant which is transformed with an expression vector comprising a DNA encoding the protein and is expressing the polypeptide are disclosed. Further, a method for detecting an ADP receptor P2T<SUB>AC </SUB>ligand, antagonist, or agonist by using the screening tool for an antiplatelet agent, and a method for screening an antiplatelet agent by the detecting method are disclosed.
AU2002210982A 2000-11-01 2001-10-31 Method of screening antiplatelet Abandoned AU2002210982A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2000-334721 2000-11-01
JP2000334721 2000-11-01
JP2001003577 2001-01-11
JP2001-003577 2001-01-11
PCT/JP2001/009534 WO2002036631A1 (en) 2000-11-01 2001-10-31 Method of screening antiplatelet

Publications (1)

Publication Number Publication Date
AU2002210982A1 true AU2002210982A1 (en) 2002-05-15

Family

ID=26603288

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002210982A Abandoned AU2002210982A1 (en) 2000-11-01 2001-10-31 Method of screening antiplatelet

Country Status (8)

Country Link
US (1) US7405051B2 (en)
EP (1) EP1331228B1 (en)
JP (1) JP3519078B2 (en)
AT (1) ATE357457T1 (en)
AU (1) AU2002210982A1 (en)
DE (1) DE60127435T2 (en)
ES (1) ES2282304T3 (en)
WO (1) WO2002036631A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2288601A (en) 1999-12-23 2001-07-03 Millennium Pharmaceuticals, Inc. P2Y12 receptor
EP1411134A1 (en) * 2002-10-15 2004-04-21 Institut National De La Sante Et De La Recherche Medicale (Inserm) Association of the H2 haplotype of the P2Y12 receptor with an increased risk for thrombosis and peripheral arterial disease
EP1411130A1 (en) * 2002-10-15 2004-04-21 Institut National De La Sante Et De La Recherche Medicale (Inserm) Association of the H2 haplotype of the P2Y12 receptor with an increased risk for thrombosis and peripheral arterial disease
US20070243632A1 (en) 2003-07-08 2007-10-18 Coller Barry S Methods for measuring platelet reactivity of patients that have received drug eluting stents
US7790362B2 (en) 2003-07-08 2010-09-07 Accumetrics, Inc. Controlled platelet activation to monitor therapy of ADP antagonists
WO2005076007A2 (en) * 2004-02-03 2005-08-18 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor p2y12 (p2y12)
US7205296B2 (en) * 2004-09-29 2007-04-17 Portola Pharmaceuticals, Inc. Substituted 2H-1,3-benzoxazin-4(3H)-ones
TWI391378B (en) 2006-03-16 2013-04-01 Astellas Pharma Inc Quinolone derivative or pharmaceutically acceptable salt thereof
DE102006020385A1 (en) * 2006-04-28 2007-10-31 Dade Behring Marburg Gmbh Method and device for determining platelet function under flow conditions
DE102006020386A1 (en) * 2006-04-28 2007-10-31 Dade Behring Marburg Gmbh Method for determining platelet function under flow conditions
WO2008133155A1 (en) 2007-04-19 2008-11-06 Astellas Pharma Inc. Bicyclic heterocyclic compound
KR20100017576A (en) * 2007-05-03 2010-02-16 아큐메트릭스, 인크. Methods of measuring inhibition of platelet aggregation by thrombin receptor antagonists

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060272A (en) * 1997-05-07 2000-05-09 Human Genome Sciences, Inc. Human G-protein coupled receptors
JP2002523090A (en) * 1998-09-01 2002-07-30 ビーエーエスエフ アクチェンゲゼルシャフト Enhanced functional expression of heterologous G protein-coupled receptors
CA2348688A1 (en) * 1998-10-13 2000-04-20 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human g protein-coupled receptors
AU1712200A (en) 1998-11-06 2000-05-29 Millennium Pharmaceuticals, Inc. G-protein coupled receptors, homologous to ebv-induced gpcr 2 (ebi-2). methods to seek for ligands thereof
EP1849866B1 (en) * 1998-11-20 2008-05-21 Arena Pharmaceuticals, Inc. Human orphan G protein-coupled receptor RUP3
SE9804274D0 (en) 1998-12-10 1998-12-10 Astra Pharma Inc Novel receptor
US6689866B1 (en) 1999-03-09 2004-02-10 Curagen Corporation Polynucleotides and proteins encoded thereby
AU2288601A (en) * 1999-12-23 2001-07-03 Millennium Pharmaceuticals, Inc. P2Y12 receptor
US20010046497A1 (en) * 2000-04-21 2001-11-29 Zhang Fang Liang G-protein coupled receptor and methods
AU2001261476A1 (en) 2000-05-11 2001-11-20 Lifespan Biosciences, Inc. Nucleic acid sequences for novel gpcrs

Also Published As

Publication number Publication date
EP1331228B1 (en) 2007-03-21
ATE357457T1 (en) 2007-04-15
WO2002036631A1 (en) 2002-05-10
US20030124626A1 (en) 2003-07-03
EP1331228A1 (en) 2003-07-30
US7405051B2 (en) 2008-07-29
JPWO2002036631A1 (en) 2004-03-11
JP3519078B2 (en) 2004-04-12
ES2282304T3 (en) 2007-10-16
DE60127435T2 (en) 2007-11-29
DE60127435D1 (en) 2007-05-03
EP1331228A4 (en) 2005-01-19

Similar Documents

Publication Publication Date Title
NO20011513D0 (en) Receptor-based antagonists and method of preparation and use thereof
AU2002210982A1 (en) Method of screening antiplatelet
SG158736A1 (en) Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
WO2001098351A3 (en) G-protein coupled receptors
WO1999000410A3 (en) Human extracellular matrix proteins
WO2000015793A3 (en) Human gpcr proteins
AU2002358274A1 (en) Methods for determining polypeptide structure, function or pharmacophore from comparison of polypeptide sequences
WO2001057085A3 (en) G-protein coupled receptors
WO2004043403A3 (en) Synthetic single domain polypeptides mimicking apolipoprotein e and methods of use
EP1029916A4 (en) Human lysophosphatidic acid receptor and use thereof
AU5282600A (en) Interleukin-1 hy2 materials and methods
WO2001098323A3 (en) G-protein coupled receptors
WO1999024587A3 (en) Human phospholipase a2 protein and dna encoding it
WO2000052151A3 (en) Human secretory proteins
WO2000028032A3 (en) Human cell surface receptor proteins
WO2003000893A3 (en) Nucleic acids encoding g protein-coupled receptors
WO2001044448A3 (en) Human oxidoreductase proteins
WO2000021986A3 (en) Matrix-remodeling genes
WO2001055103A3 (en) Chimeric neuropeptide y receptors
DE60043823D1 (en) Chemokine rezeptor
WO2000065054A3 (en) Human membrane-associated proteins
WO2000011204A3 (en) Homer interacting proteins
WO2001067106A3 (en) Identification of g protein-coupled receptor ligands and modulators
WO2000060082A3 (en) Vesicle associated proteins
WO2003025134A3 (en) mcFP ENCODING NUCLEIC ACIDS, POLYPEPTIDES, ANTIBODIES AND METHODS OF USE THEREOF